No tall buildings can now come up around Ram temple in Ayodhya
The authority has put up signs in various places warning people not to construct tall buildings.
The authority has clarified its intent by placing notice boards at various locations in the Ayodhya area according to the map, regarding the implemented restrictions.
According to the information provided by the office of Ashwini Pandey, vice chairman of Ayodhya Development Authority, in the first periphery of two kilometers only 7 meters heights of the building will be permitted and in the second periphery of four kilometers 15 meters heights will be permitted.
Ayodhya: Under 'Master Plan 2031', the Ayodhya Development Authority has declared areas around the Ram temple as restricted zones and barred the construction of tall buildings around it.
The authority has put up signs in various places warning people not to construct tall buildings.
The authority has clarified its intent by placing notice boards at various locations in the Ayodhya area according to the map, regarding the implemented restrictions.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Cervecería Nacional CFD: Calcula cuánto podrías ganar invirtiendo solo $100
Empieza a invertir
Inscríbete ahora
Undo
According to the information provided by the office of Ashwini Pandey, vice chairman of Ayodhya Development Authority, in the first periphery of two kilometers only 7 meters heights of the building will be permitted and in the second periphery of four kilometers 15 meters heights will be permitted.
Follow more information on
Air India plane crash in Ahmedabad here
. Get
real-time live updates
on rescue operations and check
full list of passengers onboard AI 171
.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
18 minutes ago
- Time of India
Indonesia launches 5-year US dollar Islamic bond, 10-year green sukuk, term sheet shows
Indonesia launched on Wednesday a five-year U.S. dollar denominated Islamic bond , or sukuk, at 4.85% initial price guidance and a 10-year green sukuk at 5.5%, according to a term sheet. The term sheet was seen by Reuters on Wednesday. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Undo
Time of India
19 minutes ago
- Time of India
'India will see $25 billion in IPOs over a year'
Representative image As IPO fundraising hits new highs, Citi is leading the charge. The top M&A and equity banker last year, Citi aims to repeat its performance with a 2-percentage-point market share gain, focusing on impactful deals over smaller sub-Rs 500-crore IPOs. In an interview with TOI, investment banking head Rahul Saraf discusses the market scenario. Excerpts: How's the deal-making environment currently? The markets are very active and will likely remain so. There's strong activity both on the M&A and equity sides, and each deal has a reason behind it. It's not just about rich valuations. Private equity is churning capital - if they get big investments they also need exits. Large conglomerates are carving out businesses for IPOs as they reach a certain scale. On the M&A front, some MNCs are selling out as they reassess relevance and capital allocation in India. Our job is to identify these triggers earlier than most. In the context of MNC exits, is it because of the advantage enjoyed by local players? It's more about aggression - an Indian entrepreneur's risk appetite is very different from that of a European boardroom. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Live Update: The Strategy Uses By Successful Intraday Trader TradeWise Learn More Undo Global firms often face structural constraints in addressing tier-2 and tier-3 markets. Many foreign firms are realising they're no longer among the top players, and that initial advantages in capital and technology have diminished. In 6-7 out of 10 such cases, that's the shift we are seeing. What makes you confident this will be a strong year for IPOs... as some issues listed below offer price in the previous year? It depends on your investment horizon. Hyundai's IPO - the largest ever in India - is now trading well above its issue price. The market is more sophisticated today. We're seeing a robust pipeline with several Rs 8,000-10,000-crore sized IPOs expected over the next 12 months. My estimate is we'll see $25 billion in IPOs and another $15-20 billion in QIPs and blocks. These are largely driven by private equity exits, MNCs, and large corporate carve-outs. Even if valuations stay flat, these transactions will continue, because they are strategically important and there is no issue in terms of demand for quality companies. The only question is what price. Most examples you've cited of equity transactions are offer-for-sale. Is that a concern? That's the current trend. The traditional view was that IPOs should raise primary capital for growth. Now, investors are comfortable if the company is already well-capitalised. Private equity exits via OFS are accepted if the company doesn't need new funds. The key is that high-quality paper is entering the market, deepening it. Some ask, is there a valuation froth? But that is because there is a liquidity trap in India as money cannot go out of the country leading to a lot of domestic liquidity. If India continues to grow as planned, as and when quality paper comes in, those excesses in some pockets will get evened out. If India's economy is doing so well, why is FDI so low? Private equity and sovereign wealth funds will continue to invest in India - they're financial investors, focused on returns and exit multiples. But for strategic investors, it's different. Their decisions depend on available cash, strategic relevance of investing in India, shareholder expectations, and whether capital can be deployed more efficiently elsewhere. Would poor Q1 numbers slow IPO activity? It's hard to predict the market in the short term. Fundamentals matter over 12-36 months, but markets move minute by minute. If Q1 is soft, there may be some temporary impact. But the long-term trajectory matters more. If the broader economy remains on track, short-term volatility won't derail IPOs. Liquidity is abundant, and markets look ahead, not behind. A weak quarter might delay an IPO or impact valuation in a specific case, but overall activity should remain strong. Even if markets stay flat for a year, IPOs will continue. Some argue valuations are unsustainably high... Valuations are always relative. From a European lens, India looks expensive. But peers in India may trade at 20x earnings, so 15x here isn't high. India's valuations have risen due to consistent flows, growth, and political stability. Today we're at 21-22x, compared to a 20-year average of 18x - not excessive. In contrast, some global markets have de-rated sharply. India's higher multiples reflect its stronger outlook. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
29 minutes ago
- Time of India
US pharma threats: Donald Trump says ‘very high tariff' for drug companies by the end of month; semiconductors to follow soon
US President Donald Trump said that he is likely to impose tariffs on imported pharmaceuticals by the end of the month, with levies on semiconductors possibly following soon after. The announcement signals an escalation in his broader 'reciprocal tariff' strategy, set to formally take effect from 1 August. Speaking to reporters on Tuesday (local time) after attending an AI summit in Pittsburgh, Trump said, 'Probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff.' He added that tariffs on semiconductors were on a 'similar' timeline and would be 'less complicated' to enforce, Bloomberg reported. Earlier this month, Trump had already pledged a 50% tariff on copper and warned that pharmaceutical tariffs could rise as high as 200% after a one-year grace period for companies to shift production back to the US. His administration is pursuing these tariffs under Section 232 of the Trade Expansion Act of 1962, claiming that the volume of drug imports poses a national security threat. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Providers are furious: Internet access without a subscription! Techno Mag Learn More Undo If enacted, the pharmaceutical levies could directly impact multinational drugmakers such as Eli Lilly, Merck, and Pfizer, who rely heavily on overseas production. Meanwhile, chip tariffs are expected to affect not only semiconductor manufacturers but also consumer tech giants like Apple and Samsung, potentially driving up prices for smartphones and laptops. The threat comes as Trump has issued tariff letters to several trading partners in recent days, outlining import duties unilaterally, though he insists negotiations are still on the table. Earlier on Tuesday, Trump also announced a revised deal with Indonesia, cutting its proposed tariff rate from 32% to 19%, in exchange for multibillion-dollar US purchases, including 50 Boeing aircraft. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
